Published in J Lipid Res on October 01, 1984
Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA (1999) 11.23
Improving diagnostic accuracy and interobserver concordance in the classification and grading of primary gliomas. Cancer (1997) 3.58
Current neurosurgical management and the impact of the extent of resection in the treatment of malignant gliomas of childhood: a report of the Children's Cancer Group trial no. CCG-945. J Neurosurg (1998) 2.75
Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis. J Clin Invest (1997) 2.33
Effects of interleukin-1 on bone turnover in normal mice. Endocrinology (1989) 2.06
Biochemical and radiologic improvement in Paget's disease of bone treated with alendronate: a randomized, placebo-controlled trial. Am J Med (1996) 2.00
Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Fosamax International Trial Study Group. Osteoporos Int (1999) 1.98
Low body mass index is an important risk factor for low bone mass and increased bone loss in early postmenopausal women. Early Postmenopausal Intervention Cohort (EPIC) study group. J Bone Miner Res (1999) 1.95
Randomized phase III trial in childhood high-grade astrocytoma comparing vincristine, lomustine, and prednisone with the eight-drugs-in-1-day regimen. Childrens Cancer Group. J Clin Oncol (1995) 1.94
Small cell architecture--a histological equivalent of EGFR amplification in glioblastoma multiforme? J Neuropathol Exp Neurol (2001) 1.91
Alendronate prevents postmenopausal bone loss in women without osteoporosis. A double-blind, randomized, controlled trial. Alendronate Osteoporosis Prevention Study Group. Ann Intern Med (1998) 1.84
Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. Early Postmenopausal Intervention Cohort Study Group. N Engl J Med (1998) 1.81
Alendronate and estrogen effects in postmenopausal women with low bone mineral density. Alendronate/Estrogen Study Group. J Clin Endocrinol Metab (2000) 1.58
Both hypothyroidism and hyperthyroidism enhance low density lipoprotein oxidation. J Clin Endocrinol Metab (1997) 1.55
Cyclosporin prevents diabetes in BB Wistar rats. Lancet (1983) 1.50
Survival following intensive chemotherapy with bone marrow reconstitution for children with recurrent intracranial ependymoma--a report of the Children's Cancer Group. J Neurooncol (1998) 1.48
Effect of alendronate on limited-activity days and bed-disability days caused by back pain in postmenopausal women with existing vertebral fractures. Fracture Intervention Trial Research Group. Arch Intern Med (2000) 1.47
Mechanism of malignant hypercalcaemia in carcinoma of the breast. Br Med J (Clin Res Ed) (1985) 1.45
Age and TP53 mutation frequency in childhood malignant gliomas: results in a multi-institutional cohort. Cancer Res (2001) 1.45
Intravenous clodronate in the treatment and retreatment of Paget's disease of bone. Lancet (1985) 1.42
Is alendronate clinically gastrotoxic? Re: Graham et al. primary amino-bisphosphonates: a new class of gastrotoxic drugs--comparison of alendronate and aspirin. Am J Gastroenterol (1998) 1.40
Bilateral testicular cancer: a preventable problem? Experience from a large cancer centre. BJU Int (2003) 1.38
Biochemical and histological evidence that carcinoma of the prostate is associated with increased bone resorption. Eur J Surg Oncol (1987) 1.34
Myoclonic epilepsy and ragged-red fibers with cytochrome oxidase deficiency: neuropathology, biochemistry, and molecular genetics. Ann Neurol (1989) 1.28
A preoperative decolonization protocol for staphylococcus aureus prevents orthopaedic infections. Clin Orthop Relat Res (2008) 1.26
Urology in a modern health centre. Br Med J (1975) 1.26
Polyneuropathy and IgM monoclonal gammopathy: studies on the pathogenetic role of anti-myelin-associated glycoprotein antibody. Ann Neurol (1985) 1.20
Diphosphonates and phosphate homoeostasis in man. Clin Sci (Lond) (1988) 1.20
Creutzfeldt-Jakob disease presenting as progressive aphasia. J Natl Med Assoc (1985) 1.18
Intracardiac myxomas. Literature review and report of six cases, one successfully treated. Am Surg (1966) 1.18
A rodent model of spontaneous stereotypy: initial characterization of developmental, environmental, and neurobiological factors. Physiol Behav (1999) 1.16
Gastric inhibitory polypeptide (GIP) stimulated by fat ingestion in man. J Clin Endocrinol Metab (1975) 1.15
Brain tumors in childhood. Childs Brain (1979) 1.15
Comparative study of alendronate versus etidronate for the treatment of Paget's disease of bone. J Clin Endocrinol Metab (1996) 1.15
Immobilisation hypercalcaemia in adults and treatment with clodronate. Br Med J (Clin Res Ed) (1984) 1.14
Body size accounts for most differences in bone density between Asian and Caucasian women. The EPIC (Early Postmenopausal Interventional Cohort) Study Group. Calcif Tissue Int (1996) 1.13
An immunophenotypic survey of malignant melanomas. Histopathology (1993) 1.13
Pilot study of high-dose thiotepa and etoposide with autologous bone marrow rescue in children and young adults with recurrent CNS tumors. The Children's Cancer Group. J Clin Oncol (1996) 1.13
Comparative effects of intravenous diphosphonates on calcium and skeletal metabolism in man. Bone (1987) 1.12
The syndrome of occult rupture of the spleen. Arch Surg (1969) 1.12
The combined effect of tumor-produced parathyroid hormone-related protein and transforming growth factor-alpha enhance hypercalcemia in vivo and bone resorption in vitro. J Clin Endocrinol Metab (1993) 1.11
Endogenous GD3 ganglioside induces apoptosis in U-1242 MG glioma cells. J Neurochem (2006) 1.10
Clinical and biochemical abnormalities in coppersmiths exposed to cadmium. Lancet (1976) 1.10
Development of spontaneous stereotyped behavior in deer mice: effects of early and late exposure to a more complex environment. Dev Psychobiol (2000) 1.09
Role of glucocorticoids in management of malignant hypercalcaemia. Br Med J (Clin Res Ed) (1984) 1.07
Monitoring of alendronate treatment and prediction of effect on bone mass by biochemical markers in the early postmenopausal intervention cohort study. J Clin Endocrinol Metab (1999) 1.05
Assays of serum lipase: analytical and clinical considerations. Clin Chem (1986) 1.05
Psychological deficit. Annu Rev Psychol (1966) 1.04
Effective short term treatment of Paget's disease with oral etidronate. Br Med J (Clin Res Ed) (1986) 1.03
Treatment of high-grade spinal cord astrocytoma of childhood with "8-in-1" chemotherapy and radiotherapy: a pilot study of CCG-945. Children's Cancer Group. J Neurosurg (1998) 1.02
Bisphosphonate effects and the bone remodeling transient. J Bone Miner Res (1997) 1.02
Intracranial chordoma in infancy. Case report. J Neurosurg (1975) 1.02
Oral alendronate induces progressive increases in bone mass of the spine, hip, and total body over 3 years in postmenopausal women with osteoporosis. Bone (1996) 1.00
Relation of axon membrane to myelin membrane in sciatic nerve during development: comparison of morphological and chemical parameters. Brain Res (1976) 1.00
Boron neutron capture therapy of a rat glioma. Neurosurgery (1990) 0.98
Hypertensive encephalopathy: complication in children treated for myeloproliferative disorders--report of three cases. Radiology (2000) 0.97
Foam cells of rabbit atheromatous lesion. Identification and cholesterol uptake in isolated cells. Lab Invest (1971) 0.97
Spontaneous stereotypy in an animal model of Down syndrome: Ts65Dn mice. Behav Genet (2001) 0.97
A study of intracellular orthophosphate concentration in human muscle and erythrocytes by 31P nuclear magnetic resonance spectroscopy and selective chemical assay. Clin Sci (Lond) (1986) 0.96
Measuring serum calcium. Br Med J (Clin Res Ed) (1985) 0.96
Proximal motor neuropathy in the BB-Wistar rat. Diabetes (1982) 0.95
Stimulation of pancreatic secretion of water and electrolytes by furosemide. Gastroenterology (1977) 0.94
Isolation and characterization of a monomethioninesulfoxide variant of interferon alpha-2b. Pharm Res (1996) 0.94
Bolus injections of recombinant human interleukin-1 cause transient hypocalcemia in normal mice. Endocrinology (1989) 0.94
Over-representation of PPARgamma sequence variants in sporadic cases of glioblastoma multiforme: preliminary evidence for common low penetrance modifiers for brain tumour risk in the general population. J Med Genet (2000) 0.93
Lipid composition of human neural tumors. J Lipid Res (1979) 0.93
In vivo effects of human recombinant transforming growth factor beta on bone turnover in normal mice. J Bone Miner Res (1990) 0.92
Regulation of lymphocyte responses by human gangliosides. I. Characteristics of inhibitory effects and the induction of impaired activation. J Immunol (1980) 0.92
Benign parotid enlargement in bulimia. Ann Intern Med (1980) 0.92
Prediction of fracture risk by radiographic absorptiometry and quantitative ultrasound: a prospective study. Calcif Tissue Int (1998) 0.92
Fibrosing pseudotumor of the sella and parasellar area producing hypopituitarism and multiple cranial nerve palsies. Neurosurgery (1993) 0.91
Pathological lesions in the spontaneously diabetic BB Wistar rat: a comprehensive autopsy study. Metabolism (1983) 0.91
Brainstem immaturity in sudden infant death syndrome: a quantitative rapid Golgi study of dendritic spines in 95 infants. Brain Res (1985) 0.91
Treatment of malignant hypercalcaemia with clodronate. Br J Cancer (1985) 0.90
A comparative study of the glycolipids of human, bird and fish testes and of human sperm. Biochim Biophys Acta (1976) 0.89
Decreased serum C-peptide/insulin molar ratios after oral glucose ingestion in hyperthyroid patients. Diabetes Care (1984) 0.89
A review and predictive models of ganglioside uptake by biological membranes. J Neurochem (1993) 0.89
The spontaneously diabetic BB Wistar rat. Morphologic and physiologic studies of peripheral nerve. J Neurol Sci (1981) 0.89
Interaction of erythrocyte membranes with particulates. Environ Health Perspect (1983) 0.89
Irreducible dorsal interphalangeal great toe dislocation. Orthopedics (1992) 0.88
Coexistence of diabetes mellitus, optic atrophy, and sensorineural deafness: case report. Ann Ophthalmol (1986) 0.88
Gangliosides inhibit platelet-derived growth factor-stimulated growth, receptor phosphorylation, and dimerization in neuroblastoma SH-SY5Y cells. J Neurochem (1995) 0.87
Duration of effect of oral diphosphonate therapy in Paget's disease of bone. Q J Med (1987) 0.87
Alendronate in early postmenopausal women: effects on bone mass during long-term treatment and after withdrawal. Alendronate Osteoporosis Prevention Study Group. J Clin Endocrinol Metab (2000) 0.87
Glycolipids and myelin proteins in human oligodendrogliomas. Glycoconj J (1996) 0.87
Hypocholesterolemic and antiaggregatory properties of 2-hydroxytetronic acid redox analogues an their relationship to clofibric acid. J Med Chem (1982) 0.87
Gangliosides inhibit growth factor-stimulated neurite outgrowth in SH-SY5Y human neuroblastoma cells. J Neurosci Res (1997) 0.87
Pseudomonas aeruginosa sepsis following retrograde cholangiopancreatography (ERCP). Dig Dis Sci (1982) 0.87
Distal symmetric polyneuropathy in the spontaneously diabetic BB-wistar rat. An ultrastructural and teased fiber study. Acta Neuropathol (1982) 0.86
Cyclosporine: action, pharmacokinetics, and effect in the BB rat model. Metabolism (1983) 0.86
Regimen-related toxicity of myeloablative chemotherapy with BCNU, thiotepa, and etoposide followed by autologous stem cell rescue for children with newly diagnosed glioblastoma multiforme: report from the Children's Cancer Group. Med Pediatr Oncol (1999) 0.86
Effects of alendronate on bone quality and remodeling in glucocorticoid-induced osteoporosis: a histomorphometric analysis of transiliac biopsies. J Bone Miner Res (2000) 0.86
Gangliosides inhibit platelet-derived growth factor-stimulated receptor dimerization in human glioma U-1242MG and Swiss 3T3 cells. J Neurochem (1993) 0.85
Androgen sensitivity of skeletal muscle: nondependence on the motor nerve in the frog forearm. Exp Neurol (1986) 0.85
A multicenter study of the influence of fat and lean mass on bone mineral content: evidence for differences in their relative influence at major fracture sites. Early Postmenopausal Intervention Cohort (EPIC) Study Group. Am J Clin Nutr (1996) 0.85
Type III hyperlipoproteinemia: development of a VLDL ApoE gel isoelectric focusing technique and application in family studies. J Lab Clin Med (1979) 0.85
Aminohexane diphosphonate in the treatment of Paget's disease of bone. J Bone Miner Res (1987) 0.84
Treatment of the hypercalcaemia of malignancy with intravenous clodronate. Bone (1987) 0.84